Cat. No. | Species | Product Description | Structure | Purity | Feature |
---|---|---|---|---|---|
CD4-H5246 | Human | Human CD24 Protein, His Tag-Ferritin | ![]() |
![]() ![]() |
![]() ![]() |
CD4-C52H4 | Cynomolgus | Cynomolgus CD24 Protein, His Tag | ![]() |
![]() ![]() |
|
CD4-C52H5 | Cynomolgus | Cynomolgus CD24 Protein, His Tag | ![]() |
![]() ![]() |
|
CD4-H52H5 | Human | Human CD24 Protein, His Tag (Nanoparticle) |
![]() ![]() |
![]() ![]() |
|
CD4-C8254 | Cynomolgus | Biotinylated Cynomolgus CD24 Protein, Fc Tag, ultra sensitivity (primary amine labeling) | ![]() |
![]() ![]() |
|
CD4-C5257 | Cynomolgus | Cynomolgus CD24 Protein, Fc Tag | ![]() |
![]() ![]() |
|
CD4-M52H7 | Mouse | Mouse CD24 Protein, His Tag | ![]() |
![]() ![]() |
|
CD4-H5257 | Human | Human CD24 Protein, Mouse IgG2a Fc Tag | ![]() |
![]() ![]() |
![]() ![]() |
CD4-H82E9 | Human | Biotinylated Human CD24 Protein, His,Avitag™ | ![]() |
![]() ![]() |
![]() ![]() |
CD4-H52H3 | Human | Human CD24 Protein, His Tag | ![]() |
![]() ![]() |
![]() ![]() |
CD4-H82F5 | Human | Biotinylated Human CD24 Protein, Fc,Avitag™ | ![]() |
![]() ![]() |
![]() ![]() |
CD4-H5254 | Human | Human CD24 Protein, Fc Tag | ![]() |
![]() ![]() |
![]() ![]() |
Immobilized Human CD24 Protein, His Tag (Cat. No. CD4-H52H5) at 5 μg/mL (100 μL/well) can bind Anti-CD24 MAb (SN3) with a linear range of 5-78 ng/mL (QC tested).
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
IBD-0333 | IBD-0333; IBD0333 | Phase 2 Clinical | SunHo (China) BioPharmaceutical Co Ltd | Solid tumours; Neoplasms; Lymphoma, Non-Hodgkin | Details |
ATG-031 | ATG-031; ATN-031 | Phase 1 Clinical | Antengene Corporation Co Ltd | Lymphoma, B-Cell; Solid tumours; Hematologic Neoplasms | Details |
NXA-01 | NXA01; NXA-01 | Phase 1 Clinical | Beijing Xingkangyuan Biotechnology Co Ltd | Solid tumours | Details |
IMM-47 | IMM-47 | Phase 1 Clinical | ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd | Solid tumours; Neoplasms | Details |
KH-801 | KH-801; KH801 | Phase 1 Clinical | Chengdu Kanghong Pharmaceutical Group Co Ltd | Solid tumours; Neoplasms | Details |
ONC-841 | ONC-841 | Phase 1 Clinical | AcroImmune Group | Solid tumours; Neoplasms | Details |
This web search service is supported by Google Inc.